Oklo stock slides in late trade as Meta nuclear deal meets insider selling and long timelines
13 January 2026
2 mins read

Oklo stock slides in late trade as Meta nuclear deal meets insider selling and long timelines

New York, January 13, 2026, 3:27 PM ET — Regular session

  • Oklo shares fell about 3% in afternoon trading after an early pop.
  • Meta-backed Ohio buildout and a recent DOE pilot agreement remain the key near-term story drivers.
  • A January 9 filing showed CEO Jacob DeWitte sold shares under a pre-set trading plan.

Oklo Inc. shares (OKLO) were down 3.3% at $99.10 in late afternoon trading on Tuesday, after swinging from an intraday high of $107.55 to a low of $98.04. The stock closed at $102.50 in the prior session.

The pullback comes as nuclear-linked stocks stay headline-driven, with Big Tech hunting for round-the-clock power to run data centers and AI workloads. Meta Platforms last week lined up nuclear agreements with Vistra and also teamed with Oklo and Bill Gates-backed TerraPower to develop small modular reactors (SMRs) — smaller nuclear units meant to be built in parts and assembled on site — in a push that could total about 6.6 gigawatts by 2035, a Reuters report said.

Oklo said its agreement with Meta supports plans for a 1.2-gigawatt power campus in Pike County, Ohio, and includes a mechanism for Meta to prepay for power and fund early work, including fuel procurement and Phase 1 development. Pre-construction and site characterization are slated to begin in 2026, with the first phase targeted as early as 2030 and a buildout to 1.2 GW by 2034, the company said. “A major step in moving advanced nuclear forward,” CEO Jacob DeWitte said, while Meta’s Urvi Parekh said, “By investing in baseload nuclear energy, we’re helping build a resilient and sustainable future” — baseload meaning steady power that runs day and night. (Oklo)

Oklo has also pointed investors to work outside power generation. It said on Jan. 7 it signed a U.S. Department of Energy “Other Transaction Agreement” — a type of federal contracting tool — to support a radioisotope pilot plant under the DOE Reactor Pilot Program, and that its Atomic Alchemy unit withdrew an earlier Nuclear Regulatory Commission construction permit application for a separate facility at Idaho National Laboratory to focus resources on the pilot. “Framework for execution and risk reduction,” DeWitte said.

Traders have also had to digest insider sales disclosed in filings after the recent run-up. A Form 4 filed on Jan. 9 showed DeWitte sold shares on Jan. 7-8 under a Rule 10b5-1 plan adopted on March 31, 2025 — a pre-arranged trading plan that can let insiders sell stock on a set schedule — and held 834,937 shares directly after the transactions.

Moves across the nuclear and power complex were more muted on Tuesday. Vistra was little changed, Constellation Energy dipped about 0.2%, and NuScale Power fell about 1.2%, leaving Oklo as the sharper mover on the day.

Part of the tension is timing. Deals can validate demand, but most of the heavy work — permitting, supply chain, fuel, and construction — sits well down the road, and the stock has to trade through that gap.

But the downside case is familiar for early-stage nuclear developers: regulatory delays, cost overruns, fuel supply constraints and financing needs can push schedules out and dilute shareholders, even when customer interest looks solid.

Next up, investors will look for any added detail on financing and milestones tied to the Ohio project, and for updates on execution under the DOE pilot agreement. Oklo’s next earnings release is expected around March 23, according to Zacks Investment Research.

Stock Market Today

  • Aktis Oncology valuation under scrutiny after price move and ongoing losses
    January 13, 2026, 3:54 PM EST. Aktis Oncology (AKTS) has drawn attention after a roughly 3% intraday move and a 20.83% year-to-date gain as investors reassess its clinical radiopharmaceutical pipeline against a tight financial profile. The company posted US$5.56 million in revenue but a US$60.649 million loss, underscoring funding needs and ongoing clinical/regulatory risk. With negative equity, AKTS reports a Price-to-Book (-8.6x) that defies conventional comparisons (peer average ~3.8x; biotech industry ~2.7x). The negative equity makes the P/B metric less meaningful, highlighting capital-structure risk rather than a clear discount or premium. Liabilities are described as higher-risk funding sources. Readers should weigh the fundraising outlook and potential catalysts against the clinical timeline when judging entry points.
Asana stock drops 7% today as software names slide after CPI — what to watch next
Previous Story

Asana stock drops 7% today as software names slide after CPI — what to watch next

Go toTop